1 completed, 1 withdrawn. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow AVL3288: new trials by email Literature Review of AVL3288 trials Research Report on AVL3288
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine Placebo, Nicotine, AVL-3288 - Cognitive Change | Phase 1 | Withdrawn | University of Maryland, Baltimore | 2018-05-01 | 2024-11-06 | |
| Clinical Trial of AVL-3288 in Schizophrenia Patients AVL-3288, Placebo - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | New York State Psychiatric Institute | 24 | 2016-11-01 | 2019-01-22 |
Psychotic Disorders (1) · Schizophrenia (1)
New York State Psychiatric Institute (1) · University of Maryland, Baltimore (1)
United States (1)
U01MH094247 (1)